Clinical Trial Update: A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study completed to determine the relative bioavailability of the MEK inhibitor trametinib in subjects with solid tumor malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• MEKINIST (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED